More on RDTCF
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.09 |
|
|||
| Open | $0.09 | ||||
| 52 Wk High | $2.16 | ||||
| 52 Wk Low | $2.16 | ||||
| Day High | $0.09 | ||||
| Day Low | $0.09 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,000 | ||||
- Rapid Dose Therapeutics and Aavishkar Granted Monolayer QuickStrip(TM) Nicotine Patent, Advancing RDT's Global Commercialization Strategy
- Rapid Dose Therapeutics (DOSE) (RDTCF) and Bodhi Health Expand Distribution and Sales of CurcuWIN(R) QuickStrip(TM) Curcumin Across Canada
- Rapid Dose Therapeutics Extends Strategic Collaboration with Global Nicotine Leader and Initiating Saudi Arabia Commercialization
- Rapid Dose Therapeutics (DOSE) (RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets
- Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
- Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory
- Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market
- Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip(TM) Platform
- Rapid Dose Therapeutics Begins Trading on the OTCQB in the United States Under Symbol RDTCF, Expanding Access for U.S. Healthcare and Biotechnology Investors
- Rapid Dose Therapeutics Launches QuickStrip(TM) Medical Cannabis for Patients in Brazil following ANVISA Approval of Sublingual and Buccal Formats for Medical Treatment
Entities mentioned with RDTCF
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
